Microarray-based gene expression profiling as a clinical tool for breast cancer management: Are we there yet?

International Journal of Surgical Pathology

Volumn 17, Issue 4, 2009, Pages 285-302

  Correa Geyer, Felipe ^a   Reis Filho, Jorge Sergio ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Gene expression; Gene signature; Microarray; Predictive; Prognostic

Indexed keywords

ANTHRACYCLINE; COMPLEMENTARY DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ESTROGEN RECEPTOR; PLACEBO; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADENOID CYSTIC CARCINOMA; APOCRINE CARCINOMA; ASPIRATION BIOPSY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER THERAPY; CLINICAL TRIAL; GENE AMPLIFICATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE MUTATION; GENETIC ENGINEERING; GENOMICS; HISTOLOGY; HISTOPATHOLOGY; HORMONAL THERAPY; HUMAN; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; MEDULLARY CARCINOMA; MICROARRAY ANALYSIS; MICROENVIRONMENT; MOLECULAR GENETICS; MORPHOLOGY; MUCINOUS CARCINOMA; NEUROENDOCRINE TUMOR; OUTCOME ASSESSMENT; PAPILLARY CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; STROMA; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PATHOLOGY, SURGICAL; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 68349126950     PISSN: 10668969     EISSN: None     Source Type: Journal    
DOI: 10.1177/1066896908328577     Document Type: Review

References (159)

1. Reis-Filho JS, Simpson PT, Gale T., et al. The molecular genetics of breast cancer: the contribution of comparative genomic hybridization. Pathol Res Pract. 2005 ; 201: 713-725.
2. Simpson PT, Reis-Filho JS, Gale T., et al. Molecular evolution of breast cancer. J Pathol. 2005 ; 205: 248-254.
3. Nahta R., Esteva FJ Trastuzumab: triumphs and tribulations. Oncogene 2007 ; 26: 3637-3643.
4. Perou CM, Sorlie T., Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000 ; 406: 747-752.
5. Sorlie T., Perou CM, Tibshirani R., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001 ; 98: 10869-10874.
6. Hu Z., Fan C., Oh DS, et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics. 2006 ; 7: 96.
7. Sorlie T., Tibshirani R., Parker J., et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003 ; 100: 8418-8423.
8. Bergamaschi A., Tagliabue E., Sorlie T., et al. Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome. J Pathol. 2008 ; 214: 357-367.
9. Chang HY, Sneddon JB, Alizadeh AA, et al. Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol. 2004 ; 2: E7.
10. Finak G., Bertos N., Pepin F., et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat Med. 2008 ; 14: 518-527. (Pubitemid 351655218)
11. Hess KR, Anderson K., Symmans WF, et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol. 2006 ; 24: 4236-4244.
12. Ivshina AV, George J., Senko O., et al. Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res. 2006 ; 66: 10292-10301.
13. Liu J., Campen A., Huang S., et al. Identification of a gene signature in cell cycle pathway for breast cancer prognosis using gene expression profiling data. BMC Med Genom. 2008 ; 1: 39.
14. Liu R., Wang X., Chen GY, et al. The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med. 2007 ; 356: 217-226.
15. Loi S., Haibe-Kains B., Desmedt C., et al. Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen. BMC Genomics. 2008 ; 9: 239.
16. Ma XJ, Salunga R., Dahiya S., et al. A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early stage breast cancer. Clin Cancer Res. 2008 ; 14: 2601-2608.
17. Ma XJ, Wang Z., Ryan PD, et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell. 2004 ; 5: 607-616.
18. Paik S., Shak S., Tang G., et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004 ; 351: 2817-2826.
19. Ring BZ, Seitz RS, Beck R., et al. Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast cancer. J Clin Oncol. 2006 ; 24: 3039-3047.
20. Sotiriou C., Wirapati P., Loi S., et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst. 2006 ; 98: 262-272.
21. Teschendorff AE, Caldas C. A robust classifier of high predictive value to identify good prognosis patients in ER negative breast cancer. Breast Cancer Res. 2008 ; 10: R73.
22. van't Veer LJ, Dai H., van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002 ; 415: 530-536.
23. Wang Y., Klijn JG, Zhang Y., et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet. 2005 ; 365: 671-679.
24. West RB, Nuyten DS, Subramanian S., et al. Determination of stromal signatures in breast carcinoma. PLoS Biol. 2005 ; 3: e187.
25. He YD, Friend SH Microarrays-the 21st century divining rod ? Nat Med. 2001 ; 7: 658-659.
26. Andre F., Mazouni C., Hortobagyi GN, et al. DNA arrays as predictors of efficacy of adjuvant/neoadjuvant chemotherapy in breast cancer patients: current data and issues on study design. Biochim Biophys Acta. 2006 ; 1766: 197-204.
27. Andre F., Pusztai L. Molecular classification of breast cancer: implications for selection of adjuvant chemotherapy. Nat Clin Pract Oncol. 2006 ; 3: 621-632. (Pubitemid 44669717)
28. Tordai A., Wang J., Andre F., et al. Evaluation of biological pathways involved in chemotherapy response in breast cancer. Breast Cancer Res. 2008 ; 10: R37.
29. Harris L., Fritsche H., Mennel R., et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007 ; 25: 5287-5312. (Pubitemid 350232263)
30. Dunkler D., Michiels S., Schemper M. Gene expression profiling: does it add predictive accuracy to clinical characteristics in cancer prognosis ? Eur J Cancer. 2007 ; 43: 745-751.
31. Lu X., Lu X., Wang ZC, et al. Predicting features of breast cancer with gene expression patterns. Breast Cancer Res Treat. 2008 ; 108: 191-201.
32. Michiels S., Koscielny S., Hill C. Prediction of cancer outcome with microarrays: a multiple random validation strategy. Lancet. 2005 ; 365: 488-492. (Pubitemid 40215731)
33. Michiels S., Koscielny S., Hill C. Interpretation of microarray data in cancer. Br J Cancer. 2007 ; 96: 1155-1158.
34. Wirapati P., Sotiriou C., Kunkel S., et al. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res. 2008 ; 10: R65.
35. Brenton JD, Carey LA, Ahmed AA, et al. Molecular classification and molecular forecasting of breast cancer: ready for clinical application ? J Clin Oncol. 2005 ; 23: 7350-7360.
36. Reis-Filho JS, Westbury C., Pierga JY The impact of expression profiling on prognostic and predictive testing in breast cancer. J Clin Pathol. 2006 ; 59: 225-231.
37. Rouzier R., Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res. 2005 ; 11: 5678-5685.
38. Geyer CE, Forster J., Lindquist D., et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006 ; 355: 2733-2743.
39. Joensuu H., Kellokumpu-Lehtinen PL, Bono P., et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med. 2006 ; 354: 809-820.
40. Piccart-Gebhart MJ, Procter M., Leyland-Jones B., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005 ; 353: 1659-1672.
41. Romond EH, Perez EA, Bryant J., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005 ; 353: 1673-1684.
42. Slamon DJ, Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001 ; 344: 783-792.
43. Abd El-Rehim DM, Pinder SE, Paish CE, et al. Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol. 2004 ; 203: 661-671.
44. Gusterson BA, Ross DT, Heath VJ, et al. Basal cytokeratins and their relationship to the cellular origin and functional classification of breast cancer. Breast Cancer Res. 2005 ; 7: 143-148.
45. Nielsen TO, Hsu FD, Jensen K., et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004 ; 10: 5367-5374.
46. Rakha EA, Putti TC, Abd El-Rehim DM, et al. Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation. J Pathol. 2006 ; 208: 495-506.
47. Savage K., Lambros MB, Robertson D., et al. Caveolin 1 is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinomas: a morphologic, ultrastructural, immunohistochemical, and in situ hybridization analysis. Clin Cancer Res. 2007 ; 13: 90-101.
48. Savage K., Leung S., Todd SK, et al. Distribution and significance of caveolin 2 expression in normal breast and invasive breast cancer: an immunofluorescence and immunohistochemical analysis. Breast Cancer Res Treat. 2008 ; 110: 245-256.
49. Turner NC, Reis-Filho JS Basal-like breast cancer and the BRCA1 phenotype. Oncogene 2006 ; 25: 5846-5853.
50. van de Rijn M., Perou CM, Tibshirani R., et al. Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol. 2002 ; 161: 1991-1996.
51. Parry S., Savage K., Marchio C., et al. Nestin is expressed in basal-like and triple-negative breast cancers. J Clin Pathol. 2008 ; 61: 1045-1050.
52. Gilbert JA, Goetz MP, Reynolds CA, et al. Molecular analysis of metaplastic breast carcinoma: high EGFR copy number via aneusomy. Mol Cancer Ther. 2008 ; 7: 944-951.
53. Fulford LG, Easton DF, Reis-Filho JS, et al. Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast. Histopathology. 2006 ; 49: 22-34.
54. Livasy CA, Karaca G., Nanda R., et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol. 2006 ; 19: 264-271.
55. Reis-Filho JS, Milanezi F., Steele D., et al. Metaplastic breast carcinomas are basal-like tumours. Histopathology. 2006 ; 49: 10-21.
56. Turner NC, Reis-Filho JS, Russell AM, et al. BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene 2007 ; 26: 2126-2132.
57. Liu X., Holstege H., van der Gulden H., et al. Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer. Proc Natl Acad Sci U S A. 2007 ; 104: 12111-12116.
58. McCarthy A., Savage K., Gabriel A., et al. A mouse model of basal-like breast carcinoma with metaplastic elements. J Pathol. 2007 ; 211: 389-398.
59. Dairkee SH, Mayall BH, Smith HS, et al. Monoclonal marker that predicts early recurrence of breast cancer. Lancet. 1987 ; 1: 514.
60. Gould VE, Koukoulis GK, Jansson DS, et al. Coexpression patterns of vimentin and glial filament protein with cytokeratins in the normal, hyperplastic, and neoplastic breast. Am J Pathol. 1990 ; 137: 1143-1155.
61. Malzahn K., Mitze M., Thoenes M., et al. Biological and prognostic significance of stratified epithelial cytokeratins in infiltrating ductal breast carcinomas. Virchows Arch 1998 ; 433: 119-129.
62. Murad TM, Scharpelli DG The ultrastructure of medullary and scirrhous mammary duct carcinoma. Am J Pathol. 1967 ; 50: 335-360.
63. Santini D., Ceccarelli C., Taffurelli M., et al. Differentiation pathways in primary invasive breast carcinoma as suggested by intermediate filament and biopathological marker expression. J Pathol. 1996 ; 179: 386-391.
64. Banerjee S., Reis-Filho JS, Ashley S., et al. Basal-like breast carcinomas: clinical outcome and response to chemotherapy. J Clin Pathol. 2006 ; 59: 729-735.
65. Rakha EA, El-Sayed ME, Green AR, et al. Prognostic markers in triple-negative breast cancer. Cancer 2007 ; 109: 25-32.
66. Rakha EA, Tan DS, Foulkes WD, et al. Are triple-negative tumours and basal-like breast cancer synonymous? Breast Cancer Res. 2007 ; 9: 404 ; author reply 405.
67. Bertucci F., Finetti P., Cervera N., et al. How basal are triple-negative breast cancers ? Int J Cancer. 2008 ; 123: 236-240.
68. Cheang MC, Voduc D., Bajdik C., et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res. 2008 ; 14: 1368-1376.
69. Rakha EA, Reis-Filho JS, Ellis IO Basal-like breast cancer: a critical review. J Clin Oncol. 2008 ; 26: 2568-2581.
70. Rakha EA, Reis-Filho JS, Ellis IO Impact of basal-like breast carcinoma determination for a more specific therapy. Pathobiology. 2008 ; 75: 95-103.
71. Calza S., Hall P., Auer G., et al. Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients. Breast Cancer Res. 2006 ; 8: R34.
72. Jumppanen M., Gruvberger-Saal S., Kauraniemi P., et al. Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers. Breast Cancer Res. 2007 ; 9: R16.
73. Tan DS, Marchió C., Jones RL, Savage K., Smith IE, Dowsett M., Reis-Filho JS Triple-negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast Cancer Res Treat. 2008 ; 111: 27-44.
74. Mullins M., Perreard L., Quackenbush JF, et al. Agreement in breast cancer classification between microarray and quantitative reverse transcription PCR from fresh-frozen and formalin-fixed, paraffin-embedded tissues. Clin Chem. 2007 ; 53: 1273-1279.
75. Parker J., Mullins M., Cheang MC, et al. A supervised risk predictor of breast cancer based on biological subtypes. ASCO Meeting Abstract May 20 2008: 11008.
76. Perreard L., Fan C., Quackenbush JF, et al. Classification and risk stratification of invasive breast carcinomas using a real-time quantitative RT-PCR assay. Breast Cancer Res. 2006 ; 8: R23.
77. Farmer P., Bonnefoi H., Becette V., et al. Identification of molecular apocrine breast tumours by microarray analysis. Oncogene. 2005 ; 24: 4660-4671.
78. Herschkowitz JI, Simin K., Weigman VJ, et al. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol. 2007 ; 8: R76.
79. Weigelt B., Horlings H., Kreike B., et al. Refinement of breast cancer classification by molecular characterization of histological special types. J Pathol. 2008 ; 216: 141-150.
80. Marchio C., Iravani M., Natrajan R., et al. Genomic and immunophenotypical characterization of pure micropapillary carcinomas of the breast. J Pathol. 2008 ; 215: 398-410.
81. Abdel-Fatah TM, Powe DG, Hodi Z., et al. High frequency of coexistence of columnar cell lesions, lobular neoplasia, and low grade ductal carcinoma in situ with invasive tubular carcinoma and invasive lobular carcinoma. Am J Surg Pathol. 2007 ; 31: 417-426.
82. Abdel-Fatah TM, Powe DG, Hodi Z., et al. Morphologic and molecular evolutionary pathways of low nuclear grade invasive breast cancers and their putative precursor lesions: further evidence to support the concept of low nuclear grade breast neoplasia family. Am J Surg Pathol. 2008 ; 32: 513-523.
83. Weigelt B., Kreike B., Reis-Filho JS Metaplastic breast carcinomas are basal-like breast cancers: a genomic profiling analysis. Breast Cancer Res Treat. 2008 Sep 25. [Epub ahead of print]
84. Tognon C., Knezevich SR, Huntsman D., et al. Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. Cancer Cell. 2002 ; 2: 367-376.
85. Diallo R., Schaefer KL, Bankfalvi A., et al. Secretory carcinoma of the breast: a distinct variant of invasive ductal carcinoma assessed by comparative genomic hybridization and immunohistochemistry. Hum Pathol. 2003 ; 34: 1299-1305.
86. Diallo R., Tognon C., Knezevich SR, et al. Secretory carcinoma of the breast: a genetically defined carcinoma entity. Verh Dtsch Ges Pathol. 2003 ; 87: 193-203.
87. Makretsov N., He M., Hayes M., et al. A fluorescence in situ hybridization study of ETV6-NTRK3 fusion gene in secretory breast carcinoma. Genes Chromosomes Cancer. 2004 ; 40: 152-157.
88. Reis-Filho JS, Natrajan R., Vatcheva R., et al. Is acinic cell carcinoma a variant of secretory carcinoma? A FISH study using ETV6 "split apart" probes. Histopathology. 2008 ; 52: 840-846.
89. Galea MH, Blamey RW, Elston CE, et al. The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat. 1992 ; 22: 207-219.
90. Goldhirsch A., Wood WC, Gelber RD, et al. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol. 2007 ; 18: 1133-1144.
91. Eifel P., Axelson JA, Costa J., et al. National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst. 2001 ; 93: 979-989.
92. Bueno-de-Mesquita JM, van Harten WH, Retel VP, et al. Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER). Lancet Oncol. 2007 ; 8: 1079-1087.
93. Buyse M., Loi S., van't Veer L., et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst. 2006 ; 98: 1183-1192.
94. Mook S., Schmidt MK, Viale G., et al. The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study. Breast Cancer Res Treat. 2008 Jul 27. [Epub ahead of print]
95. van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002 ; 347: 1999-2009.
96. Cardoso F., Van't Veer L., Rutgers E., et al. Clinical application of the 70-gene profile: the MINDACT trial. J Clin Oncol. 2008 ; 26: 729-735.
97. Desmedt C., Piette F., Loi S., et al. Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res. 2007 ; 13: 3207-3214.
98. Foekens JA, Atkins D., Zhang Y., et al. Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer. J Clin Oncol. 2006 ; 24: 1665-1671.
99. Kreike B., van Kouwenhove M., Horlings H., et al. Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res. 2007 ; 9: R65.
100. Chang HY, Nuyten DS, Sneddon JB, et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci U S A. 2005 ; 102: 3738-3743.
101. Al-Hajj M., Wicha MS, Benito-Hernandez A., et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003 ; 100: 3983-3988. (Pubitemid 36418143)
102. Ioannidis JP Microarrays and molecular research: noise discovery ? Lancet. 2005 ; 365: 454-455.
103. Eden P., Ritz C., Rose C., et al. "Good old" clinical markers have similar power in breast cancer prognosis as microarray gene expression profilers. Eur J Cancer. 2004 ; 40: 1837-1841.
104. Ein-Dor L., Zuk O., Domany E. Thousands of samples are needed to generate a robust gene list for predicting outcome in cancer. Proc Natl Acad Sci U S A. 2006 ; 103: 5923-5928.
105. Simon R. Roadmap for developing and validating therapeutically relevant genomic classifiers. J Clin Oncol. 2005 ; 23: 7332-7341.
106. Simon R., Radmacher MD, Dobbin K., et al. Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. J Natl Cancer Inst. 2003 ; 95: 14-18. (Pubitemid 36124291)
107. Shi L., Reid LH, Jones WD, et al. The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nat Biotechnol. 2006 ; 24: 1151-1161.
108. Penland SK, Keku TO, Torrice C., et al. RNA expression analysis of formalin-fixed paraffin-embedded tumors. Lab Invest. 2007 ; 87: 383-391.
109. Ravo M., Mutarelli M., Ferraro L., et al. Quantitative expression profiling of highly degraded RNA from formalin-fixed, paraffin-embedded breast tumor biopsies by oligonucleotide microarrays. Lab Invest. 2008 ; 88: 430-440.
110. Habel LA, Shak S., Jacobs MK, et al. A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res. 2006 ; 8: R25.
111. Paik S., Tang G., Shak S., et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006 ; 24: 3726-3734.
112. Goldstein LJ, Gray R., Badve S., et al. Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol. 2008 ; 26: 4063-4071.
113. Flanagan MB, Dabbs DJ, Brufsky AM, et al. Histopathologic variables predict Oncotype DXtrade mark Recurrence Score. Mod Pathol. 2008 ; 21: 1255-1261.
114. Paik S. Development and clinical utility of a 21-gene recurrence score prognostic assay in patients with early breast cancer treated with tamoxifen. Oncologist. 2007 ; 12: 631-635.
115. Ross JS, Hatzis C., Symmans WF, et al. Commercialized multigene predictors of clinical outcome for breast cancer. Oncologist. 2008 ; 13: 477-493.
116. Wolf I., Ben-Baruch N., Shapira-Frommer R., et al. Association between standard clinical and pathologic characteristics and the 21-gene recurrence score in breast cancer patients: a population-based study. Cancer 2008 ; 112: 731-736.
117. Buerger H., Mommers EC, Littmann R., et al. Ductal invasive G2 and G3 carcinomas of the breast are the end stages of at least two different lines of genetic evolution. J Pathol. 2001 ; 194: 165-170.
118. Buerger H., Otterbach F., Simon R., et al. Different genetic pathways in the evolution of invasive breast cancer are associated with distinct morphological subtypes. J Pathol. 1999 ; 189: 521-526.
119. Roylance R., Gorman P., Harris W., et al. Comparative genomic hybridization of breast tumors stratified by histological grade reveals new insights into the biological progression of breast cancer. Cancer Res. 1999 ; 59: 1433-1436.
120. Ma XJ, Salunga R., Tuggle JT, et al. Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci U S A. 2003 ; 100: 5974-5979.
121. Elston CW, Ellis IO Pathological prognostic factors in breast cancer, I: the value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991 ; 19: 403-410.
122. Robbins P., Pinder S., de Klerk N., et al. Histological grading of breast carcinomas: a study of interobserver agreement. Hum Pathol. 1995 ; 26: 873-879.
123. Loi S., Haibe-Kains B., Desmedt C., et al. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol. 2007 ; 25: 1239-1246.
124. Desmedt C., Sotiriou C. Proliferation: the most prominent predictor of clinical outcome in breast cancer. Cell Cycle. 2006 ; 5: 2198-2202.
125. Sotiriou C., Piccart MJ Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care ? Nat Rev. 2007 ; 7: 545-553.
126. Desmedt C., Haibe-Kains B., Wirapati P., et al. Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res. 2008 ; 14: 5158-5165.
127. Reid JF, Lusa L., De Cecco L., et al. Limits of predictive models using microarray data for breast cancer clinical treatment outcome. J Natl Cancer Inst. 2005 ; 97: 927-930.
128. Goetz MP, Suman VJ, Ingle JN, et al. A two-gene expression ratio of homeobox 13 and interleukin-17B receptor for prediction of recurrence and survival in women receiving adjuvant tamoxifen. Clin Cancer Res. 2006 ; 12: 2080-2087.
129. Ma XJ, Hilsenbeck SG, Wang W., et al. The HOXB13: IL17BR expression index is a prognostic factor in early-stage breast cancer. J Clin Oncol. 2006 ; 24: 4611-4619.
130. Ayers M., Symmans WF, Stec J., et al. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol. 2004 ; 22: 2284-2293. (Pubitemid 41115384)
131. Chang JC, Wooten EC, Tsimelzon A., et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet. 2003 ; 362: 362-369.
132. Folgueira MA, Carraro DM, Brentani H., et al. Gene expression profile associated with response to doxorubicin-based therapy in breast cancer. Clin Cancer Res. 2005 ; 11: 7434-7443.
133. Iwao-Koizumi K., Matoba R., Ueno N., et al. Prediction of docetaxel response in human breast cancer by gene expression profiling. J Clin Oncol. 2005 ; 23: 422-431.
134. Pierga JY, Reis-Filho JS, Cleator SJ, et al. Microarray-based comparative genomic hybridisation of breast cancer patients receiving neoadjuvant chemotherapy. Br J Cancer. 2007 ; 96: 341-351.
135. Kuerer HM, Newman LA, Smith TL, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol. 1999 ; 17: 460-469.
136. Gianni L., Zambetti M., Clark K., et al. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol. 2005 ; 23: 7265-7277.
137. Lee JK, Havaleshko DM, Cho H., et al. A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery. Proc Natl Acad Sci U S A. 2007 ; 104: 13086-13091.
138. Potti A., Dressman HK, Bild A., et al. Genomic signatures to guide the use of chemotherapeutics. Nat Med. 2006 ; 12: 1294-1300.
139. Cleator SJ, Powles TJ, Dexter T., et al. The effect of the stromal component of breast tumours on prediction of clinical outcome using gene expression microarray analysis. Breast Cancer Res. 2006 ; 8: R32.
140. Allinen M., Beroukhim R., Cai L., et al. Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell. 2004 ; 6: 17-32. (Pubitemid 38903159)
141. Beck AH, Espinosa I., Gilks CB, et al. The fibromatosis signature defines a robust stromal response in breast carcinoma. Lab Invest. 2008 ; 88: 591-601.
142. Casey T., Bond J., Tighe S., et al. Molecular signatures suggest a major role for stromal cells in development of invasive breast cancer. Breast Cancer Res Treat. 2008 Mar 29. [Epub ahead of print]
143. Hu M., Yao J., Carroll DK, et al. Regulation of in situ to invasive breast carcinoma transition. Cancer Cell. 2008 ; 13: 394-406.
144. Weigelt B., Bissell MJ Unraveling the microenvironmental influences on the normal mammary gland and breast cancer. Semin Cancer Biol. 2008 ; 18: 311-21.
145. Jones C., Mackay A., Grigoriadis A., et al. Expression profiling of purified normal human luminal and myoepithelial breast cells: identification of novel prognostic markers for breast cancer. Cancer Res. 2004 ; 64: 3037-3045.
146. Helleman J., Jansen MP, Ruigrok-Ritstier K., et al. Association of an extracellular matrix gene cluster with breast cancer prognosis and endocrine therapy response. Clin Cancer Res. 2008 ; 14: 5555-5564.
147. Thomassen M., Tan Q., Eiriksdottir F., et al. Comparison of gene sets for expression profiling: prediction of metastasis from low-malignant breast cancer. Clin Cancer Res. 2007 ; 13: 5355-5360. (Pubitemid 47510360)
148. Fan C., Oh DS, Wessels L., et al. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med. 2006 ; 355: 560-569.
149. Massagué J. Sorting out breast-cancer gene signatures. N Engl J Med. 2007 ; 356: 294-297.
150. Haibe-Kains B., Desmedt C., Piette F., et al. Comparison of prognostic gene expression signatures for breast cancer. BMC Genom. 2008 ; 9: 394.
151. Haibe-Kains B., Desmedt C., Sotiriou C., et al. A comparative study of survival models for breast cancer prognostication based on microarray data: does a single gene beat them all? Bioinformatic. 2008 ; 24: 2200-2208.
152. Alexe G., Dalgin GS, Scanfeld D., et al. High expression of lymphocyte-associated genes in node-negative HER2+ breast cancers correlates with lower recurrence rates. Cancer Res. 2007 ; 67: 10669-10676.
153. Calabro A., Beissbarth T., Kuner R., et al. Effects of infiltrating lymphocytes and estrogen receptor on gene expression and prognosis in breast cancer. Breast Cancer Res Treat. 2008 Jul 1. [Epub ahead of print]
154. Schmidt M., Bohm D., von Torne C., et al. The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res. 2008 ; 68: 5405-5413.
155. Teschendorff AE, Miremadi A., Pinder SE, et al. An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol. 2007 ; 8: R157.
156. Kahvejian A., Quackenbush J., Thompson JF What would you do if you could sequence everything ? Nat Biotechnol. 2008 ; 26: 1125-1133.
157. Ledford H. The death of microarrays? Nature 2008 ; 455: 847.
158. Shendure J. The beginning of the end for microarrays ? Nat Methods. 2008 ; 5: 585-587.
159. Rosai J. Why microscopy will remain a cornerstone of surgical pathology. Lab Invest. 2007 ; 87: 403-408.